arrow
S

Suresh Senan

amsterdam university medical centre
H指数:95
被引数:4.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy

SUNRAY-02:奥莫罗西比与免疫疗法联合治疗经根治性治疗后处于II-III期KRAS G12C突变型非小细胞肺癌的研究

2026-10-010
OA
MR-Guided Adaptive Radiotherapy in Lung Cancer: Current Landscape and Future Directions

MRI引导的肺癌自适应放射治疗:当前现状与未来方向

Cancers
IF4.4
2026-09-020
OA
The survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: a systematic review and living meta-analysis of randomized controlled trials.

实体肿瘤患者联合放疗和免疫检查点抑制剂的生存影响:一项随机对照试验的系统评价和实时Meta分析。

2026-05-250
OAAI
Outcomes of stereotactic ablative radiotherapy or surgery for early-stage lung cancer in patients with interstitial lung disease

间质性肺疾病患者早期肺癌的立体定向消融放射治疗或手术治疗结果

2026-05-090
OAAI
Implementing a fully computed tomography-free online adaptive palliative radiotherapy: a one-visit workflow

实施完全无计算机断层扫描的在线自适应姑息放射治疗: 一次访问的工作流程

2026-01-010
OA
Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS)

卡铂与顺铂的生存结局以及COVID-19对铂类药物选择的影响:一项针对小细胞肺癌患者的荷兰全国登记研究(CACIS)

2025-10-020
PRE
Treatment Toxicity and Outcomes Following Definitive Radiation Therapy for Patients With Early-Stage Non-Small Cell Lung Cancers and Pre-Existing Interstitial Lung Disease—A Systematic Review and Dosimetric Analysis

早期非小细胞肺癌合并预存间质性肺疾病患者接受根治性放射治疗后的治疗毒性及预后结果——一项系统评价和剂量学分析

2025-06-270
PRE
Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial

度伐利尤单抗(D)作为局限期小细胞肺癌(LS-SCLC)的巩固治疗:ADRIATIC试验中根据既往同步化放疗(cCRT)方案和预防性脑照射(PCI)使用情况的结果

2025-02-010
PRE
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

局限期小细胞肺癌放化疗后的Durvalumab

2024-10-108
PRE
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study

ipilimumab加尼武利尤单抗联合放化疗治疗可切除和临界可切除肺癌患者的单臂试验: 增加研究

2024-09-300
OAAI